Biogen
BIIB
967 hedge funds and large institutions have $46.3B invested in Biogen in 2016 Q2 according to their latest regulatory filings, with 108 funds opening new positions, 368 increasing their positions, 348 reducing their positions, and 79 closing their positions.
37% more first-time investments, than exits
New positions opened: 108 | Existing positions closed: 79
34% more funds holding in top 10
Funds holding in top 10: 32 → 43 (+11)
2% more funds holding
Funds holding: 948 → 967 (+19)
6% more repeat investments, than reductions
Existing positions increased: 368 | Existing positions reduced: 348
7% less capital invested
Capital invested by funds: $49.9B → $46.3B (-$3.55B)
19% less call options, than puts
Call options by funds: $1.08B | Put options by funds: $1.33B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$785M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$269M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$148M |
| 4 |
CCM
Causeway Capital Management
Los Angeles,
California
|
+$129M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$127M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$541M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$462M |
| 3 |
Jennison Associates
New York
|
-$385M |
| 4 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$246M |
| 5 |
JP Morgan Chase
New York
|
-$182M |
BIIB Hedge Fund Activity: Q2 2016 in Review
967 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q2 2016, worth a combined $46.3B — down 7.1% from $49.9B a quarter earlier.
Buyers outnumbered sellers: 108 funds opened new BIIB positions and 79 closed out — a net gain of 29 holders — while 368 added to existing stakes and 348 trimmed.
The largest buyer was Viking Global Investors, adding an estimated $785M. The largest seller was Fidelity Investments, cutting an estimated $541M.
- 967 institutional investors held Biogen (BIIB) as of Q2 2016, up from 948 in Q1 2016.
- Funds reported $46.3B of Biogen stock for Q2 2016, down 7.1% quarter-over-quarter.
- 108 funds opened new Biogen positions in Q2 2016 and 79 closed out, a net change of +29 holders.
- The largest Biogen buyer in Q2 2016 was Viking Global Investors, an estimated $785M added.
- The largest Biogen seller in Q2 2016 was Fidelity Investments, an estimated $541M sold.
Based on aggregated 13F filings for Q2 2016.